Vinorelbina glenmark 30 mg capsulas blandas efg
Introduction
Prospecto: Information for the Patient
Vinorelbina Glenmark 30 mg Soft Gelatin Capsules EFG
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
- Keep this prospect, as you may need to read it again.
- If you have any doubts, consult your doctor or pharmacist.
- This medicine has been prescribed only for you, and you must not give it to others even if they have the same symptoms as you, as it may harm them.
- If you experience any adverse effects, consult your doctor or pharmacist, even if they are not listed in this prospect. See section 4.
1.Vinorelbina Glenmark and its use
2.What you need to know before starting to take Vinorelbina Glenmark
3.How to take Vinorelbina Glenmark
4.Possible adverse effects
5.Storage of Vinorelbina Glenmark
6.Contents of the package and additional informationl
1. What is Vinorelbina Glenmark and what is it used for
This medication contains the active ingredient vinorelbine (as tartrate), and belongs to a family of medications used to treat cancer called the vinca alkaloids. Vinorelbina Glenmark is used to treat some types of lung cancer and some types of breast cancer in patients aged 18 years or older.
- Non-small cell lung cancer
- Locally advanced and metastatic breast cancer
2. What you need to know before starting Vinorelbina Glenmark
section>Consultar elprotanto
- Si nopueden >
- Swallow the capsule whole with water, preferably with a light meal. Do not take it with a hot drink, as it will dissolve the capsule too quickly.
- Do notchew or suck the capsules.
- If you accidentally chew or suck a capsule, rinse your mouth thoroughly with water and inform your doctorimmediately.
- If you vomit a few hours after taking the medication, contact your doctor;do not repeat the dose.
- Infections at different sites
- Gastrointestinal disorders; diarrhea; constipation; abdominal pain; nausea, vomiting;
- Inflammation in the mouth;
- Decreased red blood cells (anemia), which can make your skin pale and cause weakness or shortness of breath;
- Decreased platelets, which can increase the risk of bleeding or bruising;
- Decreased white blood cells, making you more vulnerable to infections;
- Loss of some reflexes, occasionally difference in touch perception;
- Loss of hair, usually mild;
- Fatigue;
- Fever;
- Uncomfortable feeling;
- Weight loss, loss of appetite.
- Difficulty coordinating muscle movements;
- Differences in vision;
- Shortness of breath, cough;
- Difficulty urinating; other genitourinary symptoms;
- Difficulty sleeping;
- Headaches; dizziness; difference in your sense of taste;
- Inflammation of the throat, difficulty swallowing food or liquids;
- Skin reactions;
- Chills;
- Weight gain;
- Pain in the joints, jaw, muscles;
- Pain in different parts of the body and pain in the tumor site;
- High blood pressure;
- Liver disorders (abnormal liver tests)
- Heart failure that can cause difficulty breathing and swelling of the ankles, irregular heartbeats;
- The lack of muscle control may be associated with abnormal gait, changes in speech, and eye movement abnormalities (ataxia).
- Blood infections (sepsis) with symptoms such as high fever and general deterioration of health;
- Heart attack (myocardial infarction);
- Gastrointestinal bleeding;
- Low sodium levels in the blood that cause weakness, muscle spasms, fatigue, confusion, and loss of consciousness. This low sodium level may be attributed in some cases to an overproduction of a hormone that causes fluid retention and (SIADH - Syndrome of Inappropriate Antidiuretic Hormone Secretion).
- Darker skin color that follows the path of the veins.
- The active ingredient is vinorelbine (as tartrate) 30 mg.
- The other components are:
Si
>Si
>Si
Si
Si
>Si
>Si
>Si
>Si
>Si>no
Si
Si
Si>
>Si>
Si>
Si>
>Si>
Si>
Si>
Si>
Si>Advert
>Advert
>Adp
>Consultar
>Consultar
>Consultar
Si
>Si
>Si>
Si>
Si>
Si>
>Si>Si
>Si>Si
Si>Si
Si>Si
Si>Si
Si>Si
Si>Si
>Si>Si
Si>Si
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si
Si>
Si
Si>
Si
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si
Si
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
Si>
3. How to Take Vinorelbina Glenmark
Before and during your treatment with vinorelbina, your doctor will check your blood cell count to determine when you receive your treatment and what dose is suitable for you. Your doctor will tell you the number and dose of capsules you should take. This will depend on the body surface area that your doctor will calculate from your weight and body height.
The usual weekly dose, taken as a single dose, is 60 mg/m2of body surface area for the first 3 doses. After the third dose, your doctor will decide if the dose will increase to 80 mg/m2of body surface area. In any case, your doctor may adjust the dose of vinorelbina.
If you are receiving the capsules with another medication to treat your cancer/condition, your doctor will decide the suitable dose for you.
The total dose should never exceed 160 mg per week. You should never take this medication more than once a week. |
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Before opening the blisters that contain vinorelbina, make sure there are no damaged capsules because the liquid inside is irritating and can be harmful if it comes into contact with your skin, eyes, or mucous membranes. If this happens, wash the affected area immediately and completely with water.
Do not ingest any damaged capsule; return it to your doctor or pharmacist. |
Taking the soft capsules of vinorelbina:
If you are taking an anti-nausea medication
Nausea and vomiting may occur with Vinorelbina Glenmark (see section "4. Possible side effects"). If your doctor has prescribed an anti-nausea medication, take it exactly as indicated.
Take vinorelbina during a light meal; this will help reduce the feeling of nausea.
If you take more Vinorelbina Glenmark than you should
If you may have taken more vinorelbina than the prescribed dose, contact your doctorimmediately.
Your body may react with intense symptoms.
Some of these symptoms may appear as signs of an infection (such as fever, chills, cough, joint pain). You may also experience severe constipation. You must immediately contact your doctor if any of these severe symptoms occur.
If you forget to take Vinorelbina Glenmark
Do not take a double dose to compensate for the missed doses. Contact your doctor, who will decide to reschedule your dose.
If you interrupt your treatment with Vinorelbina Glenmark
Your doctor will decide when to stop your treatment. However, if you want to stop your treatment earlier, discuss other options with your doctor.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
4. Possible Adverse Effects
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Contact your doctor immediatelyif you experience any of the following symptomswhile taking Vinorelbina Glenmark: -Signs of a serious infection, such as cough, fever, and chills, -Severe constipation with abdominal pain when you have not had bowel movements for several days, -Intense dizziness, dizziness when standing up, severe reduction in blood pressure, -Severe chest pain that is not normal for you, symptoms may be due to a change in heart function after poor blood flow, known as myocardial infarction (sometimes with fatal outcome)., -Difficulty breathing, dizziness, decreased blood pressure, rash affecting your entire body or swelling of the eyelids, face, lips, or throat, which may be an allergic reaction. -Chest pain, difficulty breathing, and dizziness that may be a symptom of a blood clot in a blood vessel in the lungs (pulmonary embolism), -Headaches, changes in mental state that can lead to confusion and coma, seizures, blurred vision, and high blood pressure, which could indicate a neurological disorder such as posterior reversible encephalopathy syndrome. |
Very common side effects(may affect more than 1 in 10 people)
Common side effects(may affect up to 1 in 10 people):
Rare side effects(may affect up to 1 in 100 people):
Unknown: frequency cannot be estimated from available data
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the national notification system: Spanish System of Pharmacovigilance of Medicines for Human Use. Website:www.notificaRAM.es
By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
5. Conservation of Vinorelbina Glenmark
Keep this medication out of the sight and reach of children.
Store in refrigerator (between 2°C and 8°C).
Do not use this medication after the expiration date that appears on the blister and the box after CAD. The expiration date is the last day of the month indicated.
Unused medications should not be disposed of through drains or trash. Return unused medication to your pharmacist. This will help protect the environment..
6. Contents of the packaging and additional information
Vinorelbina Glenmark Composition
Caplet content:polyethylene glycol 400, polysorbate 80 (E433), purified water
Caplet coating:gelatin 160, partially dehydrated liquid sorbitol (E420), titanium dioxide (E171), purified water, iron oxide red (E172)
Appearance of Vinorelbina Glenmark and packaging content
Vinorelbina Glenmark 30 mg soft capsules are soft, oblong, pink capsules.
Available in packs of 1 or 4 blisters, each containing 1 soft capsule.
Only some pack sizes may be marketed.
Marketing Authorization Holder and Responsible Manufacturer
Marketing Authorization Holder
Glenmark Arzneimittel GmbH
Industriestr. 31,
82194 Gröbenzell,
Germany
Responsible Manufacturer
Pharmadox Healthcare Ltd
KW20A Kordin Industrial Park
Paola, Malta
or
Alvogen Malta (Out-Licensing) Ltd
Malta Life Sciences Park,
Building 1, Level 4, Sir
Temi Zammit Buildings, San
Gwann SGN 3000, Malta
For more information about this medication, please contact the local representative of the marketing authorization holder:
Viso Farmacéutica, S.L.U.
c/ Retama 7, 7th Floor
28045 Madrid
Spain
This medication is authorized in the European Economic Area member states with the following names:
SlovakiaVinorelbine Glenmark 30 mg soft capsules
SpainVinorelbina Glenmark 30 mg soft capsules EFG
PortugalVinorelbina Glenmark
Czech RepublicVinorelbine Glenmark
Last reviewed date of this leaflet:April 2023
Further detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/)
Talk to a doctor online
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.
